Inventiva S.A. (IVA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Inventiva S.A. (IVA) Healthcare & Pipeline Overview

Inventiva S.A. is a French clinical-stage biopharmaceutical company specializing in oral small molecule therapies for diseases like NASH and MPS. Their lead candidate, Lanifibranor, is in development for NASH, while strategic collaborations with AbbVie and Boehringer Ingelheim drive innovation in autoimmune diseases and idiopathic pulmonary fibrosis.

What Is the Investment Thesis for IVA?

Inventiva S.A. presents a notable research candidate in the biotechnology sector, driven by its lead candidate Lanifibranor and strategic partnerships. Lanifibranor's potential to address the large and growing NASH market is a key value driver, with Phase III trials expected to commence. The company's collaboration with AbbVie and Boehringer Ingelheim provides financial stability and validation of its research capabilities. However, the company's negative profit margin of -7899.6% highlights the risks associated with clinical-stage biopharmaceutical companies, including the uncertainty of clinical trial outcomes and regulatory approvals. Successful Phase III results for Lanifibranor and further pipeline development are crucial for realizing the company's long-term potential. The company's beta of 0.95 indicates moderate volatility relative to the market.

Based on FMP financials and quantitative analysis

IVA Key Highlights

Market capitalization of $0.30 billion reflects investor valuation of Inventiva's pipeline and potential.

• Gross margin of 35.1% indicates the potential profitability of Inventiva's products upon commercialization.
• Lead product candidate Lanifibranor has completed Phase IIb clinical trial for NASH, demonstrating progress in clinical development.
• Strategic collaborations with AbbVie and Boehringer Ingelheim provide financial resources and expertise.
• Focus on oral small molecule therapies offers potential advantages in terms of patient convenience and compliance.

Who Are IVA's Competitors?

IVA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are IVA's Key Strengths?

Lead product candidate Lanifibranor with promising Phase IIb results.

• Strategic collaborations with AbbVie and Boehringer Ingelheim.
• Focus on oral small molecule therapies for patient convenience.
• Experienced management team with expertise in drug development.

What Are IVA's Weaknesses?

Clinical-stage company with no currently marketed products.

• Negative profit margin and reliance on external funding.
• High risk of clinical trial failure and regulatory setbacks.
• Limited financial resources compared to larger pharmaceutical companies.

What Could Drive IVA Stock Higher?

Initiation of Phase III clinical trials for Lanifibranor in NASH.

• Potential regulatory updates regarding Lanifibranor's development pathway.
• Progress in strategic collaborations with AbbVie and Boehringer Ingelheim.
• Advancement of earlier-stage programs in oncology and other diseases.

What Are the Key Risks for IVA?

Financial-distress signal — its Altman Z-Score of -6.14 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure of Phase III clinical trials for Lanifibranor.
• Regulatory delays or rejection of Lanifibranor.
• Competition from other companies developing NASH therapies.
• Dependence on external funding and strategic partnerships.

What Are the Growth Opportunities for IVA?

• Lanifibranor Phase III Trials: The successful completion of Phase III clinical trials for Lanifibranor in NASH represents a significant growth opportunity for Inventiva. Positive trial results could lead to regulatory approval and commercialization, capturing a share of the multi-billion dollar NASH market. The timeline for Phase III completion is estimated to be 2-3 years, with potential market entry by 2029. Competitive advantage lies in Lanifibranor's pan-PPAR agonist mechanism of action.
• Expansion into New Therapeutic Areas: Inventiva can leverage its expertise in drug discovery and development to expand its pipeline into new therapeutic areas beyond NASH and MPS. This could include developing therapies for other fibrotic diseases, autoimmune disorders, or oncology indications. The market size for these indications is substantial, offering significant growth potential. Timeline for new programs to reach clinical stage is estimated at 3-5 years.
• Strategic Partnerships and Collaborations: Continued strategic partnerships with pharmaceutical companies can provide Inventiva with financial resources, expertise, and access to new markets. Collaborations can accelerate the development and commercialization of its pipeline products. The value of these partnerships can range from millions to billions of dollars, depending on the scope and potential of the collaboration.
• Development of Odiparcil for MPS VI: Advancing the development of Odiparcil for MPS VI represents another growth opportunity for Inventiva. MPS VI is a rare genetic disorder with limited treatment options, creating a potential market for Odiparcil. Successful clinical development and regulatory approval could lead to commercialization and revenue generation. The timeline for potential market entry is estimated at 3-4 years.
• Geographic Expansion: Expanding its geographic presence beyond Europe can drive growth for Inventiva. Entering the US market, in particular, represents a significant opportunity, given its large pharmaceutical market and high prevalence of NASH. Establishing a commercial infrastructure in the US or partnering with a US-based company can facilitate market entry. The timeline for US market entry is estimated at 2-3 years following regulatory approval of Lanifibranor.

What Threats Does IVA Face?

• Competition from other companies developing NASH therapies.
• Regulatory hurdles and delays in drug approval.
• Patent expiration and generic competition.
• Economic downturn and reduced healthcare spending.

What Are IVA's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Expertise in oral small molecule drug development.
• Strategic collaborations with established pharmaceutical companies.
• Focus on diseases with unmet medical needs.

What Does IVA Do?

Founded in 2011 and based in Daix, France, Inventiva S.A. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for diseases with significant unmet medical needs. The company focuses on oral small molecule therapies, with a primary emphasis on non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other fibrotic and autoimmune conditions. Inventiva's lead product candidate, Lanifibranor, is a pan-PPAR agonist that has completed a Phase IIb clinical trial for the treatment of NASH, a progressive liver disease affecting millions worldwide. The company is actively preparing for Phase III trials. In addition to Lanifibranor, Inventiva is developing Odiparcil, an oral therapy for MPS VI, which has completed a Phase IIa clinical trial. Inventiva also maintains a pipeline of earlier-stage programs in oncology and other disease areas, leveraging its expertise in drug discovery and development. Strategic collaborations are a key component of Inventiva's business model. The company has partnered with AbbVie to develop and commercialize novel therapies for autoimmune diseases and with Boehringer Ingelheim International GmbH to discover and develop new treatments for idiopathic pulmonary fibrosis (IPF). These collaborations provide Inventiva with financial resources and expertise to advance its research and development programs.

What Products and Services Does IVA Offer?

• Develops oral small molecule therapies.
• Focuses on treating non-alcoholic steatohepatitis (NASH).
• Develops therapies for mucopolysaccharidoses (MPS).
• Conducts clinical trials to evaluate drug candidates.
• Collaborates with pharmaceutical companies for research and development.
• Advances a pipeline of earlier-stage programs in oncology and other diseases.

How Does IVA Make Money?

• Develops and patents novel drug candidates.
• Conducts preclinical and clinical trials to evaluate safety and efficacy.
• Out-licenses or partners with pharmaceutical companies for commercialization.
• Generates revenue through licensing fees, milestone payments, and royalties.

What Industry Does IVA Operate In?

Inventiva S.A. operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The NASH market, in particular, is expected to grow substantially in the coming years, driven by the increasing prevalence of obesity and diabetes. The competitive landscape includes established pharmaceutical companies and other biotech firms developing NASH therapies. Inventiva's strategic collaborations and focus on oral small molecule therapies position it to compete effectively in this dynamic market.

Who Are IVA's Key Customers?

• Patients suffering from NASH.
• Patients suffering from MPS VI.
• Pharmaceutical companies seeking to expand their product portfolios.
• Healthcare providers prescribing treatments for NASH and MPS.

Company Profile

Inventiva S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Daix, France.

Key Financial Metrics

Its free cash flow yield is -19.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -14.4%, the inverse of the P/E and a quick read on earnings relative to price.

IVA Valuation & Market Position

Analyst price targets span from $12.00 to $24.00, with a consensus of $15.33. At the current price of $4.14, that implies approximately 270% upside potential. Relative to its peer group, IVA's quantitative score of 16/100 is below the peer average of 84/100.

Quarterly Financial Performance: Inventiva S.A.

Revenue for Inventiva S.A. came in at $33K during Q4 FY2025, a 99.4% contraction versus the preceding quarter. The company recorded a net loss of $205.3M, with diluted EPS of $-0.32. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely. Across the four most recent quarters, IVA averaged $-1.58 in diluted EPS.

Inventiva S.A.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.14 places it in the distress zone, a signal of elevated financial risk.

Inventiva S.A. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 178.3% below estimates on average.

Wall Street analysts project Inventiva S.A. revenue of about $6.6M for fiscal 2026, with EPS near $-0.65. The estimate reflects 8 contributing analysts.

IVA Financials

IVA Latest News

IVA Analyst Consensus

IVA MoonshotScore

Common Questions About IVA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources